Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Gene therapy

Cover art: Sam Falconer

Pharmaceuticals cannot always fix a malfunctioning human body. Sometimes the only way to treat what ails a person is to tinker with their genes: the blueprints for how biological systems are built and how they operate. Some researchers are using gene-editing techniques such as CRISPR to precisely alter DNA sequences. Others are genetically modifying immune cells to imbue them with the ability to fight cancer. And in the past couple of years, there has been a rapid acceleration in the development of a wide range of treatments in which disease-causing genes are replaced in their entirety.

This Outlook therefore focuses on the rich assortment of research in which new genes are introduced into a person, usually by means of a viral vector. Successful animal experiments indicate that human genetic disorders could one day be repaired in the womb, so that a baby might enter the world disease-free. And a number of health issues that have proved difficult or impossible to remedy — such as sickle-cell disease, epilepsy and certain intractable skin conditions — might be excellent targets for gene therapy.

But gene therapy need not be limited to diseases that originate from genetic abnormalities. It might be possible to treat some viral infections with DNA, by using it to prompt the body into creating just the right monoclonal antibodies to ward off invading pathogens.

Gene therapy remains an expensive medical path, however. Moving it out of the laboratory and into the clinic will require innovative pricing schemes and regulatory policies. Along the way, clinicians, patients and policymakers will grapple with tricky ethical questions.

We are pleased to acknowledge the financial support of Pfizer Inc. in producing this Outlook. As always, Nature has sole responsibility for all editorial content.

Nature 564, S5 (2018)


This article is part of Nature Outlook: Gene therapy, an editorially independent supplement produced with the financial support of third parties. About this content.


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links